Daniel Chen

Daniel Chen, M.D., Ph.D., is a prominent figure in the field of cancer immunotherapy and synthetic biology. He is currently the Founder of both Synthetic Design Lab and Engenuity Life Sciences, roles he has held since August 2021 and January 2022, respectively, in the San Francisco Bay Area. His extensive experience includes being the Chief Medical Officer at IGM Biosciences from August 2018 to July 2021 and serving as Vice President and Global Head of Cancer Immunotherapy Development at Genentech for over 12 years, where he played a key role in the development and launch of Tecentriq, a major cancer immunotherapy drug.1

Chen's academic background includes a Bachelor of Science from the Massachusetts Institute of Technology (MIT) and an M.D./Ph.D. from the University of Southern California. He also completed his medical residency and fellowship at Stanford University School of Medicine, specializing in medical oncology and immunology.1

In addition to his professional roles, Chen has been actively involved in the Society for Immunotherapy of Cancer (SITC), where he served on the Board of Directors until December 2021 and continues to contribute to various initiatives.1 His research interests focus on advancing cancer therapies through innovative approaches in synthetic biology and immunotherapy.